Purpose: Immunoglobulin A nephropathy (IgAN) is the most common pattern of primary glomerular disease worldwide and remains a leading cause of chronic kidney disease and kidney failure. The intent of the current article is to review the 2025 Clinical Practice Guideline from Kidney Disease: Improving Global Outcomes (KDIGO) for the management of IgAN and summarize updated evidence-based diagnostic and therapeutic strategies. Method: Current literature, clinical evidence, and guideline recommendations on the management of IgAN are reviewed. Results: The updated guideline emphasizes early biopsy-confirmed diagnosis, proteinuria-guided risk assessment, and optimized supportive care, including strict blood pressure control and kidney protective therapies. In addition, newer disease-specific treatments that target pathogenic forms of IgA and IgA-immune complexes should be used simultaneously. Conclusion: The 2025 KDIGO guideline advances IgAN management through an interdisciplinary, multi-targeted, evidence-based approach aimed at reducing proteinuria, preserving kidney function, and improving long-term renal outcomes.
Romano et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: